Investor

GSK Venture Fund

Last cheque observed Jun 2015. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series BSeries CSeries E

Cheques on record
0%of best year0cheques in 12 months, 10 on record
Since the last cheque4151days00hrs00min00sec
Median round$17MRounds led0 of 10Sole investor1 roundsExits1 from the portfolioMostly inUnited States, 90%
Pitch GSK Venture Fund

GSK Venture Fund highlights

  1. 01

    10 rounds on record

  2. 02

    Mostly Series B and Series C: 50% of its rounds

  3. 03

    Sole investor in 1 rounds, median $15M

  4. 04

    1 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first10 appearances

  1. 2015

    1 round

  2. Jun
    Calporta TherapeuticsSeries A · US$10MWith 1 other
  3. 2011

    1 round

  4. Jul
    Springleaf TherapeuticsSeries B · US · sec.gov$19MWith 1 other
  5. 2010

    1 round

  6. Jul
    Anacor PharmaceuticalVenture · US · fiercebiotech.com$15MSole investor
  7. 2009

    2 rounds

  8. Feb
    diaDexusSeries F · US · deals.stage.venturebeat.com$9.2MWith 2 others
  9. Jan
    Anacor PharmaceuticalSeries E · US · bio-medicine.org$50MWith 5 others
  10. 2008

    2 rounds

  11. Apr
    Concert PharmaceuticalsSeries C · US$37MWith 11 others
  12. Feb
    CalciMedicaSeries B · US · sec.gov$5.5MWith 1 other
  13. 2007

    1 round

  14. Jan
    diaDexusSeries E · US · scalevp.com$40MWith 6 others
  15. 2006

    2 rounds

  16. Sept
    Resistentia PharmaceuticalsSeries C · SE$14MWith 4 others
  17. Jul
    Trinity BiosystemsSeries B · US$21MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

Anacor PharmaceuticalListedUndisclosedDec 2010

An exit counts when it came after the firm's first round in the company. From historical deal records.

Companies it bought

Acquisitions by the firm itself

GlycoVaxyn$190MFeb 2015

Who they invest alongside

The investors most often in the same rounds as GSK Venture Fund. A count of rooms they were both in, not a relationship either has claimed.

Baker Brothers InvestmentsGrowth equity2rounds togetherBrookside CapitalHedge fund2rounds togetherRho Capital PartnersPrivate equity2rounds togetherSanderling VenturesVC firm2rounds togetherScale Venture PartnersVC firm2rounds together

Quick answers about GSK Venture Fund

What does GSK Venture Fund invest in?

GSK Venture Fund invests most often at Series B and Series C (50% of the rounds on record).

How active is GSK Venture Fund?

10 investments on record, 0 of them in the last 12 months. The most recent was in Jun 2015.

How big are GSK Venture Fund's cheques?

The median round it joins is $17M.

Does GSK Venture Fund lead rounds?

Rarely, if at all: none of its 10 investments on record names it as the lead.

Where does GSK Venture Fund invest?

Most of the companies it backs are in the United States (90%) and Sweden (10%).

Is GSK Venture Fund investing now?

No investments in the last 12 months; the latest was in Jun 2015.

Who does GSK Venture Fund invest alongside?

Most often Baker Brothers Investments (2 rounds together), Brookside Capital (2 rounds together) and Rho Capital Partners (2 rounds together).

What kind of investor is GSK Venture Fund?

GSK Venture Fund is a growth equity firm.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it